Compare
GT Biopharma, Inc. vs Dermata Therapeutics, Inc. vs Xenetic Biosciences, Inc. vs Processa Pharmaceuticals, Inc.
| Latest fiscal year | GT Biopharma, Inc. GTBP | Dermata Therapeutics, Inc. DRMA | Xenetic Biosciences, Inc. XBIO | Processa Pharmaceuticals, Inc. PCSA |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | $2.98M | n/a |
| Revenue growth (YoY) | n/a | n/a | +19.0% | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | -95.2% | n/a |
| Net margin | n/a | n/a | -90.1% | n/a |
| Net income | -$28.35M | -$7.56M | -$2.68M | -$13.56M |
| EPS (Diluted) | -$6.68 | -$8.16 | -$1.58 | -$10.36 |
| Operating cash flow | -$12.91M | -$7.76M | -$2.29M | -$11.39M |
| Free cash flow | n/a | n/a | n/a | n/a |
| Cash & equivalents | $6.81M | $7.52M | n/a | $5.54M |
| Total assets | $8.11M | $7.86M | $8.36M | $7.81M |
| Total liabilities | n/a | $1.64M | $968.0K | $2.24M |
| Shareholders' equity | $5.79M | $6.22M | $7.40M | $5.58M |
| Return on year-end equity | -490.0% | -121.5% | -36.2% | -243.2% |
| Shares outstanding | 25.53M | 2.66M | 2.29M | 2.57M |
Revenue, most recent five fiscal years
| Fiscal year | GT Biopharma, Inc. | Dermata Therapeutics, Inc. | Xenetic Biosciences, Inc. | Processa Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | $0 Ended 2020-12-31 | n/a | $2.98M Ended 2025-12-31 | $0 Ended 2022-12-31 |
| 1 year earlier | $0 Ended 2019-12-31 | n/a | $2.50M Ended 2024-12-31 | $0 Ended 2021-12-31 |
| 2 years earlier | n/a | n/a | $2.54M Ended 2023-12-31 | n/a |
| 3 years earlier | n/a | n/a | $1.71M Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | n/a | $1.16M Ended 2021-12-31 | n/a |